Campaigners for and against assisted dying make feelings known at Westminster

Dame Prue Leith, Dame Esther Rantzen's daughter, Rebecca Wilcox, and the broadcaster, Jonathan Dimbleby, were among the high-profile figures supporting the Bill to change the law in England and Wales.
Members of the Dignity in Dying campaign wore pink and held placards in memory of friends and family members.
Those opposed to the Bill included groups dressed as scientists in white lab coats and bloodied gloves and masks, as well as nuns and other members of religious organisations.
The mood amongst campaigners was largely calm and respectful on both sides.
Dame Prue told the PA news agency she was 'both nervous and confident' about the outcome.
'It's so moving to see all these people with placards of people they've lost or people who are dying of cancer,' she said.
'It's hard not to cry because I think they have done such a good job. Let's hope we've won.'
Dame Esther Rantzen's daughter, Rebecca Wilcox, supporting the Dignity in Dying protest outside Parliament (Yui Mok/PA)
Mr Dimbleby said he believed the Bill would be 'transformative'.
He added: 'What it will mean is millions of people will be able to say to themselves, 'If I'm terminally ill, I will be able to choose, assuming I am of sound mind and I am not being coerced, to say 'Yes, I want to be assisted – I have dignity in death'.'
Rebecca Wilcox, the daughter of Dame Esther, said: 'It couldn't be a kinder, more compassionate Bill that respects choice at the end of life, that respects kindness and empathy and gives us all an option when other options, every other option, has been taken away, and it would just be the perfect tool for a palliative care doctor to have in their med bag.'
Teachers Catie and Becky Fenner said they wanted other families to benefit from the Bill.
Campaigners against the assisted dying Bill outside Parliament (Yui Mok/PA)
Their mother, who had motor neurone disease, had flown to Dignitas in Switzerland to end her life at a cost of £15,000. The sisters said they did not get to properly say goodbye and grieve and worried about the legal repercussions.
Catie, 37, said: 'We were left quite traumatised by the whole experience – not only seeing a parent go through a really horrible disease but then the secrecy of the planning.'
Campaigners against the Bill, who were gathered outside Parliament, chanted 'We are not dead yet' and 'Kill the Bill, not the ill'.
A display was erected with a gravestone reading 'RIP: The Terminally Ill Adults (End of Life) Bill. Bury it deep', and behind were two mounds meant to resemble graves.
Andrew Hilliard, 75, said he was opposed for religious reasons. He was dressed in a white lab coat with a placard reading: 'Protect our NHS from becoming the National Suicide Service'.
The chief executive of Care Not Killing, Dr Gordon Macdonald, said MPs should prioritise improving palliative care.
He said: 'Most people, when thinking about the practical implications of this, for those most vulnerable, they change their minds.'
George Fielding, a campaigner affiliated with the Not Dead Yet group which is opposed to assisted dying, said he attended to represent disabled people.
He said: 'This Bill will endanger and shorten the lives of disabled people.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

2 hours ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

South Wales Guardian

2 hours ago

• South Wales Guardian

Weight loss pill shows promise in new trial

An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Daily Mail​

2 hours ago

• Daily Mail​

BEL MOONEY: Why is it called ‘infanticide' to kill a newborn child, yet it will soon be legal to end the life of a baby when it's fully formed in the womb?

There are times in life when you shake yourself hard, as if wishing to awaken from sleep, only to find that the nightmare is all too present and frighteningly real. So I felt when our representatives in His Majesty's Government, elected MPs in the country we like to call the 'Mother of Parliaments', gave a resounding 'Yes' to making it legal for any woman to pop a pill at any time in a pregnancy – and terminate the baby in her womb.